Cancer therapies developer Theseus Pharmaceuticals wrapped its initial public offering Thursday, selling 10 million shares at $16 each, the high end of its proposed range. The stock will debut on the Nasdaq later today under the ticker symbol THRX, but shares are available for limit orders at Robinhood and other platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $2.05 - $4.20 |
| 50-day moving average | $4.02 |
| 200-day moving average | $4.47 |
| Wall St. target price | $5.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.34 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2024-02-27
| 1 week (2024-08-27) | nan% |
|---|---|
| 1 month (2024-08-03) | nan% |
| 3 months (2024-06-03) | nan% |
| 6 months (2024-03-03) | nan% |
| 1 year (2023-09-07) | -100.00% |
|---|---|
| 2 years (2022-09-07) | -100.00% |
| 3 years (2021-09-03) | N/A |
| 5 years (2019-09-03) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.89% |
| Return on equity TTM | -25.55% |
| Profit margin | 0% |
| Book value | $5.17 |
| Market Capitalization | $181.3 million |
TTM: trailing 12 months
We're not expecting Theseus Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Theseus Pharmaceuticals's shares have ranged in value from as little as $2.05 up to $4.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theseus Pharmaceuticals's is 3.984. This would suggest that Theseus Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Theseus Pharmaceuticals's beta into context you can compare it against those of similar companies.
Theseus Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.